Kane Biotech Announces a Positive Independent Research Publication on Its DispersinB Technology
WINNIPEG, MANITOBA -- (MARKETWIRE) -- 06/18/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce an independent research publication on the Company's DispersinB technology, a patent pending anti-biofilm technology. The paper appeared in the recent edition of online scientific journal 'Antimicrobial Agents and Chemotherapy' published by American Society for Microbiology.
The research findings reported in the publication, entitled "Synergistic activity of dispersin B and cefamandole nafate in the inhibition of staphylococcal growth on polyurethanes" co-authored by Dr. Gianfranco Donelli from the Department of Health, Istituto Superiore di Santa, Rome, Italy, and Dr. Jeff Kaplan from the Department of Oral Microbiology, the University of Medicine and Dentistry of New Jersey (UMDNJ), demonstrates that DispersinB is not cytotoxic and that DispersinB treatment makes bacteria growing in biofilms more susceptible to an antibiotic such as cefamandole nafate.
"This research not only provides evidence that the DispersinB enzyme is non-toxic but also demonstrates that when DispersinB is combined with an antibiotic it enhances the activity of the antibiotic against biofilm-embedded bacteria such as Staphylococcus epidermidis" stated Dr. Kaplan, also the inventor of the technology. "These findings confirm that DispersinB-antibiotic combinations provide highly effective tools for preventing bacterial colonization of medical devices, including catheters."
"This study provides solid evidence that our technology is very effective in the fight against biofilms that attach to medical devices and also demonstrates that naturally occurring DispersinB is not cytotoxic." said Gord Froehlich, President and CEO of Kane Biotech. "Our database of scientific evidence continues to grow as we prepare this technology for commercialization."
DispersinB is a novel enzyme capable of both inhibiting and dispersing bacterial biofilms. Kane Biotech has a worldwide exclusive license to all human, animal and industrial applications of DispersinB from the UMDNJ. Kane Biotech is presently using dispersinB alone, and in combination with other antimicrobial agents to develop a proprietary medical device coating.
About Dr. Jeffrey Kaplan
Jeffrey Kaplan received a Bachelor of Science degree in Biology from the University of Illinois at Chicago in 1980 and a Ph.D. in Molecular Biology from the same institution in 1985. He received postdoctoral training in the Department of Microbiology at the Albert Einstein College of Medicine, Bronx, N.Y., and in the Department of Microbiology at Columbia University, College of Physicians and Surgeons, New York, N.Y. Dr. Kaplan worked for 10 years in the Oncology Department at Wyeth Pharmaceuticals, Pearl River, N.Y., before joining the Department of Oral Biology at New Jersey Dental School in 1999.
Dr. Kaplan's lab is studying the detachment and dispersal of bacterial cells from biofilms with an emphasis on the gram-negative periodontal pathogen Aggregatibacter actinomycetemcomitans. His research is funded by the several grant agencies, including the National Institute of Health (NIH), USA. His discovery of DispersinB supported by the NIH grant was listed in the "NIH Annual Performance Report of 2004" as one of the thirteen achievements of the year.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse microbial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has a great potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Justin Gagnon Investor Relations Professional (204) 478-5602 (204) 453-1314 (FAX) Email: email@example.com Website: www.kanebiotech.com
Released June 18, 2007